Guorong Li1, An Zhao2, Michel Péoch3, Michèle Cottier4, Nicolas Mottet5. 1. Department of Urology, North Hospital, CHU of Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France; Inserm U1059, Saint-Etienne, France. Electronic address: grli2001@yahoo.fr. 2. Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Hangzhou, China. Electronic address: anzmxx@gmail.com. 3. Laboratory of Pathology, North Hospital, CHU of Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France. 4. Laboratory of Cytology, North Hospital, CHU of Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France. 5. Department of Urology, North Hospital, CHU of Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France.
Abstract
BACKGROUND: Recent findings show that cell-free miRNAs are stable in biological fluid. Urine provides an alternative to blood serum or plasma as a potential source of tumor biomarkers. MiR-210 is proven to be overexpressed in patients with a clear cell renal cell carcinoma (ccRCC). The purpose of this pilot study was to examine the urinary cell-free miR-210 as a potential tool of liquid biopsy for ccRCC. METHODS: Overall, 75 patients with a ccRCC and 45 control subjects without a cancer were included in this study. Urine samples were centrifuged twice and the cell-free urine supernanants were stored in -80°C until use. A total of 350µl cell-free urine was used for the extraction of total RNA. The expression levels of these miRNAs were performed by using quantitative RT-PCR. RESULTS: The level of urinary cell-free miR-210 was significantly higher in patients with ccRCC than in control subjects (P<0.001). The urinary cell-free miR-210 yielded the areas under the receiver operating characteristics curve of 0.76 in discriminating the patients with ccRCC from the control subjects with a sensitivity of 57.8% and a specificity of 80.0%. Moreover, the expression level of urinary cell-free miRNA-210 was significantly decreased in the patients a week after surgery (P<0.001). CONCLUSION: Urinary cell-free miR-210 may be used as a potential tool of liquid biopsy for ccRCC diagnosis. Further studies are needed to confirm our results.
BACKGROUND: Recent findings show that cell-free miRNAs are stable in biological fluid. Urine provides an alternative to blood serum or plasma as a potential source of tumor biomarkers. MiR-210 is proven to be overexpressed in patients with a clear cell renal cell carcinoma (ccRCC). The purpose of this pilot study was to examine the urinary cell-free miR-210 as a potential tool of liquid biopsy for ccRCC. METHODS: Overall, 75 patients with a ccRCC and 45 control subjects without a cancer were included in this study. Urine samples were centrifuged twice and the cell-free urine supernanants were stored in -80°C until use. A total of 350µl cell-free urine was used for the extraction of total RNA. The expression levels of these miRNAs were performed by using quantitative RT-PCR. RESULTS: The level of urinary cell-free miR-210 was significantly higher in patients with ccRCC than in control subjects (P<0.001). The urinary cell-free miR-210 yielded the areas under the receiver operating characteristics curve of 0.76 in discriminating the patients with ccRCC from the control subjects with a sensitivity of 57.8% and a specificity of 80.0%. Moreover, the expression level of urinary cell-free miRNA-210 was significantly decreased in the patients a week after surgery (P<0.001). CONCLUSION: Urinary cell-free miR-210 may be used as a potential tool of liquid biopsy for ccRCC diagnosis. Further studies are needed to confirm our results.
Authors: Michal Fedorko; Jaroslav Juracek; Michal Stanik; Marek Svoboda; Alexandr Poprach; Tomas Buchler; Dalibor Pacik; Jan Dolezel; Ondrej Slaby Journal: Biochem Med (Zagreb) Date: 2017-06-15 Impact factor: 2.313
Authors: Vincenzo Petrozza; Antonio Luigi Pastore; Giovanni Palleschi; Claudia Tito; Natale Porta; Serena Ricci; Chiara Marigliano; Manuela Costantini; Giuseppe Simone; Angelina Di Carlo; Michele Gallucci; Antonio Carbone; Francesco Fazi Journal: Oncotarget Date: 2017-06-13